P53-Mediated Senescence Impairs the Apoptotic Response to Chemotherapy and Clinical Outcome in Breast Cancer

Cancer Cell

Volumn 21, Issue 6, 2012, Pages 793-806

  Jackson, James G ^a   Pant, Vinod ^a   Li, Qin ^a,b   Chang, Leslie L ^a   Quintás Cardama, Alfonso ^a   Garza, Daniel ^a   Tavana, Omid ^a   Yang, Peirong ^a   Manshouri, Taghi ^a   Li, Yi ^c   El Naggar, Adel K ^a   Lozano, Guillermina ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; PROTEIN P53; WNT1 PROTEIN;

ALLELE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; GENE MUTATION; HETEROZYGOTE; HUMAN; HUMAN CELL; MITOSIS; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; SENESCENCE; TREATMENT RESPONSE; WILD TYPE;

EID: 84862124987     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2012.04.027     Document Type: Article

References (60)

1. Aas T., Børresen A.L., Geisler S., Smith-Sørensen B., Johnsen H., Varhaug J.E., Akslen L.A., Lønning P.E. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med. 1996, 2:811-814.
2. Acosta J.C., O'Loghlen A., Banito A., Guijarro M.V., Augert A., Raguz S., Fumagalli M., Da Costa M., Brown C., Popov N., et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 2008, 133:1006-1018.
3. Bearss D.J., Subler M.A., Hundley J.E., Troyer D.A., Salinas R.A., Windle J.J. Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors. Oncogene 2000, 19:1114-1122.
4. Begley L.A., Kasina S., Mehra R., Adsule S., Admon A.J., Lonigro R.J., Chinnaiyan A.M., Macoska J.A. CXCL5 promotes prostate cancer progression. Neoplasia 2008, 10:244-254.
5. Berns E.M., Foekens J.A., Vossen R., Look M.P., Devilee P., Henzen-Logmans S.C., van Staveren I.L., van Putten W.L., Inganäs M., Meijer-van Gelder M.E., et al. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res. 2000, 60:2155-2162.
6. Bertheau P., Plassa F., Espié M., Turpin E., de Roquancourt A., Marty M., Lerebours F., Beuzard Y., Janin A., de Thé H. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 2002, 360:852-854.
7. Bertheau P., Turpin E., Rickman D.S., Espié M., de Reyniès A., Feugeas J.P., Plassa L.F., Soliman H., Varna M., de Roquancourt A., et al. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med. 2007, 4:e90.
8. Bertheau P., Espié M., Turpin E., Lehmann J., Plassa L.F., Varna M., Janin A., de Thé H. TP53 status and response to chemotherapy in breast cancer. Pathobiology 2008, 75:132-139.
9. Bonnefoi H., Piccart M., Bogaerts J., Mauriac L., Fumoleau P., Brain E., Petit T., Rouanet P., Jassem J., Blot E., et al. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol. 2011, 12:527-539. EORTC 10994/BIG 1-00 Study Investigators.
10. Brown J.M., Attardi L.D. The role of apoptosis in cancer development and treatment response. Nat. Rev. Cancer 2005, 5:231-237.
11. Brown J.P., Wei W., Sedivy J.M. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science 1997, 277:831-834.
12. Brugarolas J., Chandrasekaran C., Gordon J.I., Beach D., Jacks T., Hannon G.J. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995, 377:552-557.
13. Bunz F., Dutriaux A., Lengauer C., Waldman T., Zhou S., Brown J.P., Sedivy J.M., Kinzler K.W., Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282:1497-1501.
14. Bunz F., Hwang P.M., Torrance C., Waldman T., Zhang Y., Dillehay L., Williams J., Lengauer C., Kinzler K.W., Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 1999, 104:263-269.
15. Carey L.A., Dees E.C., Sawyer L., Gatti L., Moore D.T., Collichio F., Ollila D.W., Sartor C.I., Graham M.L., Perou C.M. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 2007, 13:2329-2334.
16. Chang B.D., Xuan Y., Broude E.V., Zhu H., Schott B., Fang J., Roninson I.B. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 1999, 18:4808-4818.
17. Clarke A.R., Purdie C.A., Harrison D.J., Morris R.G., Bird C.C., Hooper M.L., Wyllie A.H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993, 362:849-852.
18. Clevenger C.V. Roles and regulation of stat family transcription factors in human breast cancer. Am. J. Pathol. 2004, 165:1449-1460.
19. Collado M., Gil J., Efeyan A., Guerra C., Schuhmacher A.J., Barradas M., Benguría A., Zaballos A., Flores J.M., Barbacid M., et al. Tumour biology: senescence in premalignant tumours. Nature 2005, 436:642.
20. Coppé J.P., Patil C.K., Rodier F., Sun Y., Muñoz D.P., Goldstein J., Nelson P.S., Desprez P.Y., Campisi J. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008, 6:2853-2868.
21. Deng C., Zhang P., Harper J.W., Elledge S.J., Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995, 82:675-684.
22. Dhawan P., Richmond A. Role of CXCL1 in tumorigenesis of melanoma. J. Leukoc. Biol. 2002, 72:9-18.
23. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., Medrano E.E., Linskens M., Rubelj I., Pereira-Smith O., et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA 1995, 92:9363-9367.
24. Donehower L.A., Godley L.A., Aldaz C.M., Pyle R., Shi Y.P., Pinkel D., Gray J., Bradley A., Medina D., Varmus H.E. Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev. 1995, 9:882-895.
25. Jacks T., Remington L., Williams B.O., Schmitt E.M., Halachmi S., Bronson R.T., Weinberg R.A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 1994, 4:1-7.
26. Jackson J.G., Pereira-Smith O.M. Primary and compensatory roles for RB family members at cell cycle gene promoters that are deacetylated and downregulated in doxorubicin-induced senescence of breast cancer cells. Mol. Cell. Biol. 2006, 26:2501-2510.
27. Jackson J.G., Post S.M., Lozano G. Regulation of tissue- and stimulus-specific cell fate decisions by p53 in vivo. J. Pathol. 2011, 223:127-136.
28. Karnoub A.E., Weinberg R.A. Chemokine networks and breast cancer metastasis. Breast Dis. 2006-2007, 26:75-85.
29. Komarova E.A., Kondratov R.V., Wang K., Christov K., Golovkina T.V., Goldblum J.R., Gudkov A.V. Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in mice. Oncogene 2004, 23:3265-3271.
30. Kröger N., Milde-Langosch K., Riethdorf S., Schmoor C., Schumacher M., Zander A.R., Löning T. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin. Cancer Res. 2006, 12:159-168.
31. Krtolica A., Parrinello S., Lockett S., Desprez P.Y., Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl. Acad. Sci. USA 2001, 98:12072-12077.
32. Kuilman T., Michaloglou C., Vredeveld L.C., Douma S., van Doorn R., Desmet C.J., Aarden L.A., Mooi W.J., Peeper D.S. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008, 133:1019-1031.
33. Lang G.A., Iwakuma T., Suh Y.A., Liu G., Rao V.A., Parant J.M., Valentin-Vega Y.A., Terzian T., Caldwell L.C., Strong L.C., et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004, 119:861-872.
34. Lehmann-Che J., André F., Desmedt C., Mazouni C., Giacchetti S., Turpin E., Espié M., Plassa L.F., Marty M., Bertheau P., et al. Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. Oncologist 2010, 15:246-252.
35. Liu G., Parant J.M., Lang G., Chau P., Chavez-Reyes A., El-Naggar A.K., Multani A., Chang S., Lozano G. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat. Genet. 2004, 36:63-68.
36. Lowe S.W., Ruley H.E., Jacks T., Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993, 74:957-967.
37. Lowe S.W., Schmitt E.M., Smith S.W., Osborne B.A., Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993, 362:847-849.
38. Lowe S.W., Bodis S., McClatchey A., Remington L., Ruley H.E., Fisher D.E., Housman D.E., Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science 1994, 266:807-810.
39. Makris A., Powles T.J., Dowsett M., Allred C. p53 protein overexpression and chemosensitivity in breast cancer. Lancet 1995, 345:1181-1182.
40. Mathieu M.C., Koscielny S., Le Bihan M.L., Spielmann M., Arriagada R. p53 protein overexpression and chemosensitivity in breast cancer. Lancet 1995, 345:1182. Institut Gustave-Roussy Breast Cancer Group.
41. Mazars R., Spinardi L., BenCheikh M., Simony-Lafontaine J., Jeanteur P., Theillet C. p53 mutations occur in aggressive breast cancer. Cancer Res. 1992, 52:3918-3923.
42. McGinley J.N., Knott K.K., Thompson H.J. Effect of fixation and epitope retrieval on BrdU indices in mammary carcinomas. J. Histochem. Cytochem. 2000, 48:355-362.
43. Novakova Z., Hubackova S., Kosar M., Janderova-Rossmeislova L., Dobrovolna J., Vasicova P., Vancurova M., Horejsi Z., Hozak P., Bartek J., Hodny Z. Cytokine expression and signaling in drug-induced cellular senescence. Oncogene 2010, 29:273-284.
44. Pant V., Xiong S., Iwakuma T., Quintás-Cardama A., Lozano G. Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proc. Natl. Acad. Sci. USA 2011, 108:11995-12000.
45. Pirianov G., Colston K.W. Interactions of vitamin D analogue CB1093, TNFalpha and ceramide on breast cancer cell apoptosis. Mol. Cell. Endocrinol. 2001, 172:69-78.
46. Post S.M., Quintás-Cardama A., Terzian T., Smith C., Eischen C.M., Lozano G. p53-dependent senescence delays Emu-myc-induced B-cell lymphomagenesis. Oncogene 2010, 29:1260-1269.
47. Rahko E., Blanco G., Soini Y., Bloigu R., Jukkola A. A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients. Eur. J. Cancer 2003, 39:447-453.
48. Riley T., Sontag E., Chen P., Levine A. Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol. 2008, 9:402-412.
49. Sah V.P., Attardi L.D., Mulligan G.J., Williams B.O., Bronson R.T., Jacks T. A subset of p53-deficient embryos exhibit exencephaly. Nat. Genet. 1995, 10:175-180.
50. Soussi T., Lozano G. p53 mutation heterogeneity in cancer. Biochem. Biophys. Res. Commun. 2005, 331:834-842.
51. Straver M.E., Glas A.M., Hannemann J., Wesseling J., van de Vijver M.J., Rutgers E.J., Vrancken Peeters M.J., van Tinteren H., Van't Veer L.J., Rodenhuis S. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res. Treat. 2010, 119:551-558.
52. Takamori H., Oades Z.G., Hoch O.C., Burger M., Schraufstatter I.U. Autocrine growth effect of IL-8 and GROalpha on a human pancreatic cancer cell line, Capan-1. Pancreas 2000, 21:52-56.
53. te Poele R.H., Okorokov A.L., Jardine L., Cummings J., Joel S.P. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 2002, 62:1876-1883.
54. Tsukamoto A.S., Grosschedl R., Guzman R.C., Parslow T., Varmus H.E. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 1988, 55:619-625.
55. Varna M., Lehmann-Che J., Turpin E., Marangoni E., El-Bouchtaoui M., Jeanne M., Grigoriu C., Ratajczak P., Leboeuf C., Plassa L.F., et al. p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors. Int. J. Cancer 2009, 124:991-997.
56. Wajapeyee N., Serra R.W., Zhu X., Mahalingam M., Green M.R. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 2008, 132:363-374.
57. Waldman T., Kinzler K.W., Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 1995, 55:5187-5190.
58. Waldman T., Zhang Y., Dillehay L., Yu J., Kinzler K., Vogelstein B., Williams J. Cell-cycle arrest versus cell death in cancer therapy. Nat. Med. 1997, 3:1034-1036.
59. Willis A., Jung E.J., Wakefield T., Chen X. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 2004, 23:2330-2338.
60. Yang X., Lu P., Fujii C., Nakamoto Y., Gao J.L., Kaneko S., Murphy P.M., Mukaida N. Essential contribution of a chemokine, CCL3, and its receptor, CCR1, to hepatocellular carcinoma progression. Int. J. Cancer 2006, 118:1869-1876.